Skip to search formSkip to main content

RO5424802

Known as: ALK Inhibitor RO5424802 
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ALK… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

CH5424802
Receptor Tyrosine Kinase Inhibitionalectinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib
7610 (2010). 43. Lee, J.O. et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2014
2014
Genotyping lung cancer is an investment in the future.
TO THEEDITOR:Intheircost-effectivenessanalysisof ALKtesting and crizotinib treatment, Djalalov et al 1 put a price tag on this… Expand
Is this relevant?
Review
2014
Review
2014
Review of the current targeted therapies for non-small-cell lung cancer.
The last decade has witnessed the development of oncogene-directed targeted therapies that have significantly changed the… Expand
Is this relevant?
Review
2014
Review
2014
[Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer].
The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
BACKGROUND Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?